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It is believed that growth of castration resistant prostate cancer (CRPC) cells is enabled by sensitization to
minimal residual post-castrate androgen due to overexpression of the androgen receptor (AR). Evidence
is derived from androgen-induced colony formation in the absence of cell-secreted factors or from
studies involving forced AR overexpression in hormone-dependent cells. On the other hand, standard cell
line models established from CRPC patient tumors (e.g., LNCaP and VCaP) are hormone-dependent and
require selection pressure in castrated mice to re-emerge as CRPC cells and the resulting tumors then
tend to be insensitive to the androgen antagonist enzalutamide. Therefore, we examined established
CRPC model cells produced by castration of mice bearing hormone-dependent cell line xenografts
including CRPC cells overexpressing full-length AR (C4-2) or co-expressing wtAR and splice-variant AR-
V7 that is incapable of ligand binding (22Rv1). In standard colony formation assays, C4-2 cells were
shown to be androgen-dependent and sensitive to enzalutamide whereas 22Rv1 cells were incapable of
colony formation under identical conditions. However, both C4-2 and 22Rv1 cells formed colonies in
conditioned media derived from the same cells or from HEK293 ﬁbroblasts that were proven to lack
androgenic activity. This effect was (i) not enhanced by androgen, (ii) insensitive to enzalutamide, (iii)
dependent on AR (in C4-2) and on AR-V7 and wtAR (in 22Rv1) and (iv) sensitive to inhibitors of several
signaling pathways, similar to androgen-stimulation. Therefore, during progression to CRPC in vivo,
coordinate cellular changes accompanying overexpression of AR may enable cooperation between
hormone-independent activity of AR and actions of cellular secretory factors to completely override
androgen-dependence and sensitivity to drugs targeting hormonal factors.
© 2016 Elsevier Inc. All rights reserved.1. Introduction
Growth of castration resistant prostate cancer (CRPC) may often
be supported by restoration of tumor androgen to levels
approaching or greater than pre-castration levels via de novo
intratumoral synthesis [1,2]. It has also been proposed, based on
in vitro studies, that overexpression of AR, a common feature of
clinical CRPC, sensitizes CRPC cells to much lower, castrate levels of
androgen [3e5]. In such cells, in vitro data also suggests that low
androgen may synergize with hyperactive cell signaling pathways
to support optimal tumor growth [6]. Overexpression of AR splice
variants with deletions spanning the ligand-binding pocket have
also been functionally and clinically linked to prostate cancer, Detroit, MI 48201, USA.
am).progression; in these cases expression of full-length ARmay also be
necessary [7]. Nevertheless, in patients with CRPC, treatment with
the high afﬁnity AR antagonist enzalutamide or the androgen
synthesis inhibitor abiraterone has produced limited clinical
beneﬁt [8,9]. Efforts are therefore underway to develop more
effective inhibitors of residual androgen biosynthesis as well as
higher afﬁnity androgen antagonists to treat CRPC [10,11]. In this
context, the following considerations warrant further investigation
of whether AR-overexpressing CRPC cells that develop under cas-
trate conditions are necessarily androgen-dependent in the physi-
ological secretory microenvironment of the cells.
First, the in vitro studies demonstrating androgen-dependence
of AR-overexpressing CRPC cells often relied on colony formation
assays in media containing charcoal-stripped serum. These assay
conditions are hence devoid of many serum factors and adequate
levels of factors secreted by neighboring cells because of the
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AR-overexpressing CRPC cells generated in castrated mice (e.g., C4-
2 cells) require androgen in such colony formation assays, they
grow robustly in monolayer culture in media containing charcoal-
stripped serum and are also insensitive to enzalutamide in mono-
layer cultures [12]. In fact, sensitivity of monolayer cultures and
tumor xenografts to enzalutamide is typically demonstrated using
CRPC model cells produced by forced overexpression of AR in
hormone-sensitive cell lines to render them hyper-sensitive to
androgen [11,13,14]. Another CRPC model used to demonstrate
androgen dependence comprises AR þ androgen-dependent cells
with forced expression of an AR splice variant incapable of ligand
binding [15]. Second, standard cell line models established from
metastatic CRPC patient tumors (e.g., LNCaP and VCaP) are
hormone-dependent and require selection pressure in castrated
mice to re-emerge as CRPC cells and the resulting tumors then tend
to be insensitive to the high afﬁnity androgen antagonist enzalu-
tamide [12]. This suggests that in vivo generated CRPC tumors may
be androgen-independent in contrast to CRPC model cells gener-
ated by forced AR overexpression. Third, studies demonstrating the
need for androgen to potentiate growth signaling by autocrine/
paracrine pathways in AR-overexpressing CRPC cells were focused
on activation of individual signaling pathways rather than collec-
tive activation of multiple cellular events that might render the
cells completely hormone-independent.
Therefore, we hypothesized that progression to CRPC in vivo,
associated with overexpression of endogenous wtAR, could include
cellular changes that enable the complement of cell-secreted fac-
tors to support and/or cooperate with hormone-independent AR
actions; this would override the androgen-dependence observed in
the absence of such factors. Further, overexpressed AR splice vari-
ants in CRPC cells may similarly need to cooperate with cell-
secreted factors to support hormone-independent CRPC growth.
We tested this hypothesis using the in vivo generated C4-2 CRPC
cells that overexpress full length AR. In parallel, we examined the
in vivo generated 22Rv1 CRPC cells, which overexpress a common
AR splice variant (AR-V7) in addition to expressing wtAR. C4-2 cells
and 22Rv1 cells were originally produced in mice via castration-
induced selection pressure placed on the hormone-dependent
LNCaP and CWR22 cell lines, respectively.
2. Materials and methods
VCaP cells, 22Rv1 cells were from the American Type Culture
Collection (Manassas, VA). C4-2 cells were kindly provided by Dr.
Edwin Sanchez (University of Toledo). All cell lines were routinely
maintained as previously described [16].
To prepare conditioned media, C4-2 cells, 22Rv1 cells and HEK
293 ﬁbroblasts were grown in phenol-red free RPMI 1640 medium
supplemented with 10% heat-inactivated charcoal stripped FBS for
two passages. Forty-eight hour conditioned media was then
collected, centrifuged and ﬁltered through a 0.2 m ﬁlter.
Colony formation assays, cell proliferation assays and western
blots were performed as previously described [16].
RNA isolation, reverse transcription and qPCR methods have
been described [16].
Lentivirus-mediated gene knockdown has been previously
described [16]. (shRNA sequences provided in Supplementary
Table 1).
All experiments were repeated at least three times. Statistical
signiﬁcance was determined using one-way analysis of variance.
3. Results
In media containing charcoal-stripped serum, androgen (R1881)was obligatory for colony formation of C4-2 cells (Fig. 1A) whereas
22Rv1 cells failed to form colonies either in the absence or in the
presence of R1881 (Fig. 1B). Both C4-2 cells (Fig. 1A) and 22Rv1 cells
(Fig. 1B) showed robust colony formation in 48-h conditioned
media from either the same cells or from HEK293 ﬁbroblasts grown
in media containing charcoal-stripped serum. The addition of
R1881 to either type of conditioned media did not increase the
number of colonies (Fig. 1A and B).
As structurally diverse molecules could have androgenic activ-
ity, we ﬁrst used a sensitive biological test to detect any androgenic
activity in the conditioned media used above. For this purpose, we
used VCaP cells, which are exquisitely dependent on androgen for
both survival and growth. In media containing charcoal-stripped
serum, survival of VCaP cells at the end of 4 days was reduced by
~50% (Fig.1C). The cells required at least 0.025 nM R1881 to prevent
this loss of viability and higher concentrations of R1881 were
required for cell growth (Fig. 1C). However, survival of VCaP cells in
conditionedmedia from C4-2, 22Rv1 or HEK293 cells was similar to
that in the absence of R1881. From inspection of Fig. 1C, it appears
that any androgenic activity present in the conditionedmedia must
be less than the equivalent of 0.003 nM R1881. Since, under
androgen-dependent conditions, colony formation of C4-2 cells
required 0.05 nM R1881 for optimal colony formation (Fig. 1D), it is
evident that the conditioned media did not have the level of
androgenic activity required to support colony formation.
As another test for androgenic activity in the conditioned media
we examined inhibition of colony formation by the high afﬁnity
androgen antagonist, enzalutamide. The androgen-dependent col-
ony formation of C4-2 cells (in 0.1 nM R1881) was completely
blocked by enzalutamide at concentrations of 1 mM and 10 mM but
not at 0.1 mM enzalutamide (Fig. 2A). The enzalutamide dose-
dependence for inhibition of colony formation in C4-2 cells corre-
sponded to the dose required to completely antagonize gene acti-
vation by R1881 (0.1 nM) in the same cells asmeasured for the KLK3
and TMPRSS2 genes (Fig. 2B and C). Enzalutamide did not inhibit
colony formation of C4-2 cells in conditioned media from the same
cells or HEK293 ﬁbroblasts (Fig. 2A). Similar to C4-2 cells, enzalu-
tamide did not inhibit colony formation of 22Rv1 cells in condi-
tioned media from the same cells or HEK293 ﬁbroblasts (Fig. 2D).
These results further conﬁrm lack of androgenic activity in the
conditioned media from C4-2, 22Rv1 and HEK293 cells.
Depleting AR by lentiviral transduction of targeted shRNA
abrogated the ability of conditioned media from C4-2 or HEK293
cells to support colony formation in C4-2 cells (Fig. 2E). In 22Rv1
cells, knockdown of full-length AR alone or a partial knockdown of
total AR (full length AR plus AR-V7) abrogated colony formation in
conditioned media from 22Rv1 or HEK293 ﬁbroblasts (Fig. 2F). The
results demonstrate that despite the absence of androgenic activity,
the ability of conditioned media to support colony formation is
dependent on expression of AR in both C4-2 and 22Rv1 cells.
Further, it may be noted (from the combined data in Figs.1B, 2D and
F) that, in 22Rv1 cells the full length AR is required to support
colony formation but this occurs in an androgen-independent
manner.
We used a battery of signaling pathway inhibitors (described in
Supplementary Table 2) to compare androgen-dependent colony
formation in C4-2 cells and the androgen-independent colony
formation of C4-2 and 22Rv1 cells in various conditioned media.
The androgen-dependent colony formation of C4-2 cells was pre-
vented by inhibitors of Akt, PI3-K, EGF/FGF/PDGF receptor tyrosine
kinase, Rac1 and STAT3 but not by inhibitors of FGFR, VEGFR, Src
family, c-Raf, MEK1/2, ERK, JNK and PKC (Fig. 3A). The pattern of
inhibitor sensitivity of colony formation of C4-2 cells in conditioned
media from C4-2 cells or HEK293 ﬁbroblasts was virtually identical
to that for androgen-dependent colony formation (Fig. 3B). Colony
Fig. 1. C4-2 cells (Panel A) or 22Rv1 cells (Panel B) were plated in triplicate at a density of 2000 cells/well in 6-well plates in phenol-red free RPMI 1640 medium supplemented with
10% heat-inactivated charcoal stripped FBS containing R1881 (0.1 nM) or vehicle (ethanol). In parallel, the cells were plated in conditioned media (CM) harvested from the same cells
or from HEK293 cells in the absence or in the presence of R1881 (0.1 nM). The media was replenished every 3 or 4 days. At the end of ~2 weeks, colonies were stained with crystal
violet and counted. In Panel C, VCaP cells were plated at a density of 6000 cells/well in 96-well plates in phenol-red free RPMI 1640 medium supplemented with 10% heat-
inactivated charcoal stripped FBS. The cells were treated with the indicated concentrations of R1881. In parallel, the media was replaced with conditioned media (CM) har-
vested from C4-2 cells or 22Rv1 cells or HEK293 ﬁbroblasts. After 4 days of treatment, viable cells were measured by the MTT assay. In Panel D, colony formation of C4-2 cells was
measured as described for Panel A but in the presence of the indicated concentrations of R1881.
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22Rv1 cells and HEK293 cells were both sensitive to the same in-
hibitors as C4-2 cells but were additionally sensitive to inhibitors of
MEK1/2 and ERK (Fig. 3C).
4. Discussion
Cells used as models of CRPC often comprise androgen-
dependent cells in which wtAR or a splice-variant of AR was
ectopically overexpressed; such cells continue to be sensitive to
enzalutamide in vitro and in vivo and may represent some clinical
tumors. In contrast, the studies presented here address the physi-
ological relevance of androgen-dependent signaling in prostate
cancer models that became castration resistant in vivo and over-
express AR or co-express wtAR and an AR splice variant. Such cells
may have acquired additional changes in other signaling and reg-
ulatory pathways. In the context of the present studies and avail-
able literature data, AR-dependent CRPC model cells that arose
in vivo may be characterized as follows.
Cell lines originally established from human CRPC tumors (e.g.,
LNCaP and VCaP cells) [2,17] that are entirely hormone-dependentin vitro and in vivo need to be placed under selection pressure in
castrated mice to develop into CRPC tumors. Such CRPC tumors
have proved to be enzalutamide-resistant in vivo [12]. The
hormone-sensitivity of the parental cell lines could be explained by
the possibility that their human tumors of origin may have been
supported by intratumoral androgen synthesis despite castration or
the cells may have changed during immortalization in vitro to
become androgen-dependent. A well-known example of this type
of CRPCmodels is the C4-2 cell line variant, which was generated in
castrated mice from LNCaP xenografts [18], overexpresses AR and,
as shown here, is only androgen-dependent and sensitive to
enzalutamide in the absence of cell secreted factors. Therefore,
dependence of such cells on androgen may be overridden by the
secretory tumormicroenvironment. A second example is the 22Rv1
variant cell line; this CRPC model was generated in castrated mice
from CWR22 xenografts [19] and expresses a relatively low level of
wtAR and co-expresses relatively high levels of an AR splice variant
that is unable to bind androgen. As shown here, these cells depend
on both wtAR and its splice variant as well as cellular secretory
factors. In contrast to wtAR þ cells with forced expression of an AR
splice variant [15], these cells are insensitive to androgen even in
Fig. 2. C4-2 cells (Panel A) were plated in triplicate at a density of 2000 cells/well in 6-well plates in phenol-red free RPMI 1640 medium supplemented with 10% heat-inactivated
charcoal stripped FBS containing R1881 (0.1 nM) or vehicle (ethanol) in the absence or in the presence of the indicated concentrations of enzalutamide (Enz). In parallel, the cells
were plated in conditioned media (CM) harvested from the same cells or from HEK293 cells in the absence or in the presence of Enz (10 mM). The media was replenished every 3 or 4
days. At the end of ~2 weeks, colonies were stained with crystal violet and counted. In Panels B and C, C4-2 cells were plated in phenol-red free RPMI 1640 medium supplemented
with 10% heat-inactivated charcoal stripped FBS at ~30% conﬂuency. The cells were treated with R1881 (0.1 nM) or vehicle in the absence or in the presence of the indicated
concentrations of Enz. Forty-eight hours later the cells were harvested and the relative mRNA levels for the KLK3 and TMPRSS2 genes were measured. In Panel D, 22Rv1 cells were
plated in conditioned media from the same cells or from HEK293 cells in the absence or in the presence of Enz (10 mM) and colony formation assay was performed as in Panel A. C4-2
cells (Panel E) or 22Rv1 cells (Panel F) were transduced with AR shRNA or control shRNA using lentivirus. Seventy-two hours after infection, cells were plated for the colony
formation assay as described for Panel A or harvested for western blot analysis (insets).
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Based on our studies, the synergy between AR (wild-type or
splice variant) and the cellular secretory complement (autologous
or heterologous) may at least in part be due to the action of multiple
signal transduction pathways, which also support hormonal action.The pathways show some cell type selectivity, particularly with
respect to MEK inhibition. This does not exclude a role for other
secreted factors such as micro RNAs. Nevertheless, one reason for
the limited clinical beneﬁt of targeting hormone sensitivity of AR
(with AR ligands and androgen synthesis inhibitors) in CRPC may
Fig. 3. In Panel A, C4-2 cells were in plated in triplicate at a density of 2000 cells/well in 6-well plates in phenol-red free RPMI 1640 medium supplemented with 10% heat-
inactivated charcoal stripped FBS. The cells were treated with R1881 (0.1 nM) in the absence or in the presence of the indicated concentrations of the various inhibitors noted.
In parallel (Panel B), the cells were plated in conditioned media (CM) harvested from the same cells or from HEK293 cells in the absence or in the presence of the same inhibitors. In
Panels A and B, the media were replenished every 3 or 4 days. At the end of ~2 weeks, colonies were stained with crystal violet and counted. In Panel C, 22Rv1 cells were plated in
conditioned media from the same cells or from HEK293 cells in the absence or in the presence of the inhibitors and colony formation assay was performed as in Panels A and B.
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splice variant. These hormone-independent actions of AR are sup-
ported by and/or act in concert with multiple events activated by
the tumor secretory milieu, rendering the tumors completely
insensitive to androgen.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.bbrc.2016.05.058.References
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